Repurposing drugs for use against Zika virus infectionFootnote^$

^$Presented at the 9th International Symposium on Computational Methods in Toxicology and Pharmacology Integrating Internet Resources, CMTPI-2017, 27–30 October 2017, Goa, India.

References

• B.D. Foy, K.C. Kobylinski, J.L. Chilson Foy, B.J. Blitvich, A. Travassos da Rosa, A.D. Haddow, R.S. Lanciotti, and R.B. Tesh, Probable non-vector-borne transmission of Zika virus, Colorado, USA, Emerg. Infect. Dis. 17 (2011), pp. 880–882.
   PubMed Web of Science ®Google Scholar
• S.A. Rasmussen, D.J. Jamieson, M.A. Honein, and L.R. Petersen, Zika virus and birth defects–reviewing the evidence for causality, N. Engl. J. Med. 374 (2016), pp. 1981–1987.
   PubMed Web of Science ®Google Scholar
• A. Alam, N. Imam, A. Farooqui, S. Ali, M.Z. Malika, and R. Ishrata, Recent trends in ZIKV research: A step away from cure, Biomed. Pharmacother. 91 (2017), pp. 1152–1159.
   PubMed Web of Science ®Google Scholar
• M.T. Aliota, L. Bassit, S.S. Bradrick, B. Cox, M.A. Garcia-Blanco, C. Gavegnano, T.C. Friedrich, T.G. Golos, D.E. Griffin, A.D. Haddow, E.G. Kallas, U. Kitron, M. Lecuit, D.M. Magnani, C. Marrs, N. Mercer, E. McSweegan, L.F.P. Ng, D.H. O’Connor, J.E. Osorio, G.S. Ribeiro, M. Ricciardi, S.L. Rossi, G. Saade, R.F. Schinazi, G.O. Schott-Lerner, C. Shan, P.Y. Shi, D.I. Watkins, N. Vasilakis, and S.C. Weaver, Zika in the Americas, year 2: What have we learned? What gaps remain? A report from the Global Virus Network, Antiviral Res. 144 (2017), pp. 223–246.
   PubMed Web of Science ®Google Scholar
• G.W. Dick, S.F. Kitchen, and A.J. Haddow, Zika virus. I. Isolations and serological specificity, Trans. R. Soc. Trop. Med. Hyg. 46 (1952), pp. 509–520.
   PubMed Web of Science ®Google Scholar
• G.W. Dick, Zika virus. II. Pathogenicity and physical properties, Trans. R. Soc. Trop. Med. Hyg. 46 (1952), pp. 521–534.
   PubMed Web of Science ®Google Scholar
• F.N. Macnamara, Zika virus: A report on three cases of human infection during an epidemic of jaundice in Nigeria, Trans. R. Soc. Trop. Med. Hyg. 48 (1954), pp. 139–145.
   PubMed Web of Science ®Google Scholar
• W.G. Bearcroft, Zika virus infection experimentally induced in a human volunteer, Trans. R. Soc. Trop. Med. Hyg. 50 (1956), pp. 442–448.
   PubMedGoogle Scholar
• J.P. Boorman and J.S. Porterfield, A simple technique for infection of mosquitoes with viruses transmission of Zika virus, Trans. R. Soc. Trop. Med. Hyg. 50 (1956), pp. 238–242.
   PubMedGoogle Scholar
• P. Brès, Données récentes apportées par les enquêtes sérologiques sur la prévalence des arbovirus en Afrique, avec référence spéciale à la fièvre jaune, Bull. Org. Mond. Santé 43 (1970), pp. 223–267.
   PubMedGoogle Scholar
• N.J. Marchette, R. Garcia, and A. Rudnick, Isolation of Zika virus from Aedes aegypti mosquitoes in Malaysia, Am. J. Trop. Med. Hyg. 18 (1969), pp. 411–415.
   PubMed Web of Science ®Google Scholar
• H.J. Posen, J.S. Keystone, J.B. Gubbay, and S.K. Morris, Epidemiology of Zika virus, 1947–2007, BMJ Global Health 1 (2016), pp. e000087.
   PubMed Web of Science ®Google Scholar
• M.R. Duffy, T.H. Chen, W.T. Hancock, A.M. Powers, J.L. Kool, R.S. Lanciotti, M. Pretrick, M. Marfel, S. Holzbauer, C. Dubray, L. Guillaumot, A. Griggs, M. Bel, A.J. Lambert, J. Laven, O. Kosoy, A. Panella, B.J. Biggerstaff, M. Fischer, E.B. Hayes, Zika virus outbreak on Yap Island, Federated States of Micronesia, N. Engl. J. Med. 360 (2009), pp. 2536–2543.
   PubMed Web of Science ®Google Scholar
• V.M. Cao-Lormeau, C. Roche, A. Teissier, E. Robin, A.L. Berry, H.P. Mallet, A.A. Sall, and D. Musso, Zika virus, French Polynesia, South Pacific, 2013, Emerg. Infect. Dis. 20 (2014), pp. 1085–1086.
   PubMed Web of Science ®Google Scholar
• E. Oehler, L. Watrin, P. Larre, I. Leparc-Goffart, S. Lastère, F. Valour, L. Baudouin, H.P. Mallet, D. Musso, and F. Ghawche, Zika virus infection complicated by Guillain-Barré syndrome – case report, French Polynesia, December 2013, Euro Surveill. 19 (2014), pp. 20720. Available at http://www.eurosurveillance.org/ViewArticle,aspx?ArticleId=20720
   Google Scholar
• C. Zanluca, V.C.A. de Melo, A.L.P. Mosimann, G.I.V. dos Santos, C.N.D. dos Santos, and K. Luz, First report of autochthonous transmission of Zika virus in Brazil, Mem. Inst. Oswaldo Cruz, Rio de Janeiro 110 (2015), pp. 569–572.
   PubMed Web of Science ®Google Scholar
• N. Gyawali, R.S. Bradbury, and A.W. Taylor-Robinson, The global spread of Zika virus: Is public and media concern justified in regions currently unaffected?, Infect. Dis. Poverty 5 (2016), p. 37.
   PubMed Web of Science ®Google Scholar
• A.S. Fauci and D.M. Morens, Zika virus in the Americas – yet another arbovirus threat, N. Engl. J. Med. 374 (2016), pp. 601–604.
   PubMed Web of Science ®Google Scholar
• J. Devillers, C. Lagneau, A. Lattes, J.C. Garrigues, M.M. Clemente, and A. Yébakima, In silico models for predicting vector control chemicals targeting Aedes aegypti, SAR QSAR Environ. Res. 25 (2014), pp. 805–835.
   PubMed Web of Science ®Google Scholar
• J. Devillers, A. Doucet-Panaye, and J.P. Doucet, Structure–activity relationship (SAR) modelling of mosquito larvicides, SAR QSAR Environ. Res. 26 (2015), pp. 263–278.
   PubMed Web of Science ®Google Scholar
• J.P. Doucet, E. Papa, A. Doucet-Panaye, and J. Devillers, QSAR models for predicting the toxicity of piperidine derivatives against Aedes aegypti, SAR QSAR Environ. Res. 28 (2017), pp. 451–470.
   PubMed Web of Science ®Google Scholar
• P. Wang, X. Xu, S. Liao, J. Song, G. Fan, S. Chen, and Z. Wang, Quantitative structure–activity relationship study of amide mosquito repellents, SAR QSAR Environ. Res. 28 (2017), pp. 341–353.
   PubMed Web of Science ®Google Scholar
• J.E. Knox, N.L. Ma, Z. Yin, S.J. Patel, W.L. Wang, W.L. Chan, K.R.R. Rao, G. Wang, X. Ngew, V. Patel, D. Beer, S.P. Lim, S.G. Vasudevan, and T.H. Keller, Peptide inhibitors of West Nile NS3 protease: SAR study of tetrapeptide aldehyde inhibitors, J. Med. Chem. 49 (2006), pp. 6585–6590.
   PubMed Web of Science ®Google Scholar
• T. Knehans, A. Schüller, D.N. Doan, K. Nacro, J. Hill, P. Güntert, M.S. Madhusudhan, T. Weil, and S.G. Vasudevan, Structure-guided fragment-based in silico drug design of dengue protease inhibitors, J. Comput. Aided Mol. Des. 25 (2011), pp. 263–274.
   PubMed Web of Science ®Google Scholar
• S. Gupta, A. Jadaun, H. Kumar, U. Raj, P.K. Varadwaj, and A.R. Rao, Exploration of new drug like inhibitors for serine/threonine protein phosphatase 5 of Plasmodium falciparum: A docking and simulation study, J. Biomol. Struct. Dyn. 13 (2015), pp. 1–68.
   Google Scholar
• V.K. Vyas, G. Qureshi, M. Ghate, H. Patel, and S. Dalai, Identification of novel PfDHODH inhibitors as antimalarial agents via pharmacophore-based virtual screening followed by molecular docking and in vivo antimalarial activity, SAR QSAR Environ. Res. 27 (2016), pp. 427–440.
   PubMed Web of Science ®Google Scholar
• S.P. Kumar, L.B. George, Y.T. Jasrai, and H.A. Pandya, Prioritization of active antimalarials using structural interaction profile of Plasmodium falciparum enoyl-acyl carrier protein reductase (PfENR)-triclosan derivatives, SAR QSAR Environ. Res. 26 (2015), pp. 61–77.
   PubMed Web of Science ®Google Scholar
• X. Hou, X. Chen, M. Zhang, and A. Yan, QSAR study on the antimalarial activity of Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitors, SAR QSAR Environ. Res. 27 (2016), pp. 101–124.
   PubMed Web of Science ®Google Scholar
• J. Devillers, Computational Design of Chemicals for the Control of Mosquitoes and their Diseases, CRC Press, Boca Raton, FL, 2018.
   Google Scholar
• M.M.A.K. Shawan, M.M. Hossain, M.A. Hasan, M.M. Hasan, A. Parvin, S. Akter, K.R. Uddin, S. Banik, M. Morshed, M.N. Rahman, and S.M.B. Rahman, Design and prediction of potential RNAi (siRNA) molecules for 3'UTR PTGS of different strains of Zika virus: A computational approach, Nat. Sci. 13 (2015), pp. 37–50.
   Google Scholar
• S. Fernando, T. Fernando, M. Stefanik, L. Eyer, and D. Ruzek, An approach for Zika virus inhibition using homology structure of the envelope protein, Mol. Biotechnol. 58 (2016), pp. 801–806.
   PubMed Web of Science ®Google Scholar
• K.G. Byler, I.V. Ogungbe, and W.N. Setzer, In-silico screening for anti-Zika virus phytochemicals, J. Molec. Graph. Model. 69 (2016), pp. 78–91.
   PubMed Web of Science ®Google Scholar
• S. Ekins, A.L. Perryman, and C. Horta Andrade, OpenZika: An IBM world community grid project to accelerate Zika virus drug discovery, PLoS Negl. Trop. Dis. 10 (2016), pp. e0005023.
   PubMed Web of Science ®Google Scholar
• D. Cavalla, Predictive methods in drug repurposing: Gold mine or just a bigger haystack? Drug Discov. Today 18 (2013), pp. 523–532.
   PubMed Web of Science ®Google Scholar
• E. Kincaid, A second look: Efforts to repurpose old drugs against Zika cast a wide net, Nature Med. 22 (2016), pp. 824–825.
   PubMed Web of Science ®Google Scholar
• R. Delvecchio, L.M. Higa, P. Pezzuto, A.L. Valadão, P.P. Garcez, F.L. Monteiro, E.C. Loiola, A.A. Dias, F.J.M. Silva, M.T. Aliota, E.A. Caine, J.E. Osorio, M. Bellio, D.H. O’Connor, S. Rehen, R.S. de Aquiar, A. Savarino, L. Campanati, and A. Tanuri, Chloroquine inhibits Zika virus infection in different cellular models, Viruses 8 (2016), p. E322.
   PubMed Web of Science ®Google Scholar
• G. Barbosa-Lima, L.S. da Silveira Pinto, C.R. Kaiser, J.L. Wardell, C.S. De Freitas, Y.R. Vieira, A. Marttorelli, J.C. Neto, P.T. Bozza, S.M.S.V. Wardell, M.V.N. de Souza, and T.M.L. Souza, N-(2-(arylmethylimino)ethyl)-7-chloroquinolin-4-amine derivatives, synthesized by thermal and ultrasonic means, are endowed with anti-Zika virus activity, Eur. J. Med. Chem. 127 (2017), pp. 434–441.
   PubMed Web of Science ®Google Scholar
• H. Tang, C. Hammack, S.C. Ogden, Z. Wen, X. Qian, Y. Li, B. Yao, J. Shin, F. Zhang, E.M. Lee, K.M. Christian, R.A. Didier, P. Jin, H. Song, and G.L. Ming, Zika virus infects human cortical neural progenitors and attenuates their growth, Cell Stem Cell 18 (2016), pp. 587–590.
   PubMed Web of Science ®Google Scholar
• M. Xu, E.M. Lee, Z. Wen, Y. Cheng, W.K. Huang, X. Qian, J. Tcw, J. Kouznetsova, S.C. Ogden, C. Hammack, F. Jacob, H.N. Nguyen, M. Itkin, C. Hanna, P. Shinn, C. Allen, S.G. Michael, A. Simeonov, W. Huang, K.M. Christian, A. Goate, K.J. Brennand, R. Huang, M. Xia, G.L. Ming, W. Zheng, H. Song, and H. Tang, Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen, Nature Med. 22 (2016), pp. 1101–1107.
   PubMed Web of Science ®Google Scholar
• N.J. Barrows, R.K. Campos, S.T. Powell, K.R. Prasanth, G. Schott-Lerner, R. Soto-Acosta, G. Galarza-Muñoz, E.L. McGrath, R. Urrabaz-Garza, J. Gao, P. Wu, R. Menon, G. Saade, I. Fernandez-Salas, S.L. Rossi, N. Vasilakis, A. Routh, S.S. Bradrick, and M.A. Garcia-Blanco, A screen of FDA-approved drugs for inhibitors of Zika virus infection, Cell Host Microbe 20 (2016), pp. 259–270.
   PubMed Web of Science ®Google Scholar
• A.J. Nok, Arsenicals (melarsoprol), pentamidine and suramin in the treatment of human African trypanosomiasis, Parasitol. Res. 90 (2003), pp. 71–79.
   PubMed Web of Science ®Google Scholar
• F. Hawking, Suramin: With special reference to onchocerciasis, Adv. Pharmacol. 15 (1978), pp. 289–322.
   Google Scholar
• I.C. Albulescu, M. van Hoolwerff, L.A. Wolters, E. Bottaro, C. Nastruzzi, S.C. Yang, S.C. Tsay, J.R. Hwu, E.J. Snijder, and M.J. van Hemert, Suramin inhibits chikungunya virus replication through multiple mechanisms, Antiviral Res. 121 (2015), pp. 39–46.
   PubMed Web of Science ®Google Scholar
• C. Basavannacharya and S.G. Vasudevan, Suramin inhibits helicase activity of NS3 protein of dengue virus in a fluorescence-based high throughput assay format, Biochem. Biophys. Res. Commun. 453 (2014), pp. 539–544.
   PubMed Web of Science ®Google Scholar
• I.C. Albulescu, K. Kovacikova, A. Tas, E.J. Snijder, and M.J. van Hemert, Suramin inhibits Zika virus replication by interfering with virus attachment and release of infectious particles, Aintiviral Res. 143 (2017), pp. 230–236.
   PubMed Web of Science ®Google Scholar
• C.Q. Sacramento, G.R. de Melo, C.S. de Freitas, N. Rocha, L. Villas Bôas Hoelz, M. Miranda, N. Fintelman-Rodrigues, A. Marttorelli, A.C. Ferreira, G. Barbosa-Lima, J.L. Abrantes, Y.R. Vieira, M.M. Bastos, E. de Mello Volotão, E. Portela Nunes, D.A. Tschoeke, L. Leomil, E. Correia Loiola, P. Trindade, S.K. Rehen, F.A. Bozza, P.T. Bozza, N. Boechat, F.L. Thompson, A.M.B. de Filippis, K. Brüning, and T.M.L. Souza, The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication, Sci. Rep. 7 (2017), pp. 40920.
   Web of Science ®Google Scholar
• J.F. Rossignol, Nitazoxanide: A first-in-class broad-spectrum antiviral agent, Antiviral Res. 110 (2014), pp. 94–103.
   PubMed Web of Science ®Google Scholar
• R.Y. Cao, Y.F. Xu, T.H. Zhang, J.J. Yang, Y. Yuan, P. Hao, Y. Shi, J. Zhong, and W. Zhong, Pediatric drug nitazoxanide: A potential choice for control of Zika, Brief Rep. OFID (2017), pp. 1–5, doi: 10.1093/ofid/ofx009.
   Google Scholar
• G. Greenstone, The revival of thalidomide: From tragedy to therapy, BC Med. J. 53 (2011), pp. 230–233.
   Google Scholar
• H.A. Ghofrani, I.H. Osterloh, and F. Grimminger, Sildenafil: From angina to erectile dysfunction to pulmonary hypertension and beyond, Nat. Rev. Drug Discov. 5 (2006), pp. 689–702.
   PubMed Web of Science ®Google Scholar
• P. Trouiller, P. Olliaro, E. Torreele, J. Orbinski, R. Laing, and N. Ford, Drug development for neglected diseases: A deficient market and a public-health policy failure, Lancet 359 (2002), pp. 2188–2194.
   PubMed Web of Science ®Google Scholar
• B. Pedrique, N. Strub-Wourgaft, C. Some, P. Olliaro, P. Trouiller, N. Ford, B. Pécoul, and J.H. Bradol, The drug and vaccine landscape for neglected diseases (2000–11): A systematic assessment, Lancet Glob. Health 1 (2013), pp. e371–e379.
   PubMed Web of Science ®Google Scholar
• T.I. Oprea and J.P. Overington, Computational and practical aspects of drug repositioning, Assay Drug Develop. Technol. 13 (2015), pp. 299–306.
   PubMed Web of Science ®Google Scholar